Medications as a Potential Source of Exposure to Phthalates in the US Population

被引:171
作者
Hernandez-Diaz, Sonia [1 ]
Mitchell, Allen A. [2 ]
Kelley, Katherine E. [2 ]
Calafat, Antonia M. [3 ]
Hauser, Russ [4 ,5 ]
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Pharmacoepidemiol Program, Boston, MA 02115 USA
[2] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA
[3] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA
[4] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth Occupat & Environm Med, Boston, MA 02115 USA
[5] Harvard Univ, Sch Publ Hlth, Program Epidemiol, Boston, MA 02115 USA
关键词
coating; didanosine; medications; mesalamine; omeprazole; phthalates; theophylline; DIETHYLHEXYL PHTHALATE; SEXUAL-DIFFERENTIATION; MALE INFANTS; HUMAN URINE; METABOLITES;
D O I
10.1289/ehp.11766
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
BACKGROUND: Widespread human exposure to phthalates, some of which are developmental and reproductive toxicants in experimental animals, raises concerns about potential human health risks. Underappreciated sources of exposure include phthalates in the polymers coating some oral medications. OBJECTIVE: The objective of this study was to evaluate whether users of phthalate-containing medications have higher urinary concentrations of phthalate metabolites than do nonusers. METHODS: We used publically available files from the National Health and Nutrition Examination Survey for the years 1999-2004. For certain survey periods, participants were asked to recall use of prescription medication during the past 30 days, and for a subsample of individuals, the urinary concentrations of phthalate metabolites were measured. We a priori identified medications potentially containing phthalates as inactive ingredients and then compared the mean urinary concentration of phthalate metabolites between users and nonusers of those medications. RESULTS: Of the 7,999 persons with information on urinary phthalate concentrations, 6 reported using mesalamine formulations, some of which may include dibutyl phthalate (DBP); the mean urinary concentration of monobutyl phthalate, the main DBP metabolite, among these mesalamine users was 50 times higher than the mean for nonusers (2,257 mu g/L vs. 46 mu g/L; p < 0.0001). Users of didanosine, omeprazole, and theophylline products, some of which may contain diethyl phthalate (DEP), had mean urinary concentrations of monoethyl phthalate, the main DEP metabolite, significantly higher than the mean for nonusers. CONCLUSION: Select medications might be a source of high exposure to some phthalates, one of which, DBP, shows adverse developmental and reproductive effects in laboratory animals. These results raise concern about potential human health risks, specifically among vulnerable segments of the general population and particularly pregnant women and children.
引用
收藏
页码:185 / 189
页数:5
相关论文
共 27 条
[11]  
Hornung RW., 1990, Appl Occup Environ Hyg, V5, P46, DOI DOI 10.1080/1047322X.1990.10389587
[12]   Determination of 16 phthalate metabolites in urine using automated sample preparation and on-line preconcentration/high-performance liquid chromatography/tandem mass spectrometry [J].
Kato, K ;
Silva, MJ ;
Needham, LL ;
Calafat, AM .
ANALYTICAL CHEMISTRY, 2005, 77 (09) :2985-2991
[13]  
Koch H. M., 2005, Umweltmedizin in Forschung und Praxis, V10, P144
[14]   An estimation of the daily intake of di(2-ethylhexyl)phthalate (DEHP) and other phthalates in the general population [J].
Koch, HM ;
Drexler, H ;
Angerer, J .
INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH, 2003, 206 (02) :77-83
[15]   Estimated daily phthalate exposures in a population of mothers of male infants exhibiting reduced anogenital distance [J].
Marsee, Kevin ;
Woodruff, Tracey J. ;
Axelrad, Daniel A. ;
Calafat, Antonia M. ;
Swan, Shanna H. .
ENVIRONMENTAL HEALTH PERSPECTIVES, 2006, 114 (06) :805-809
[16]  
McDowell A, 1981, Vital Health Stat 1, P1
[17]  
*NCHS, 1994, VIT HLTH STAT, V1, P1
[18]  
*NCHS, 2007, CONT NHANES WEB TUT
[19]  
*NHANES, 2005, NHANES 1999 2000 DAT
[20]  
*NHANES, 2008, DAT SETS REL DOC